Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

F. Ravandi, C. Arana Yi, J. E. Cortes, M. Levis, S. Faderl, G. Garcia-Manero, E. Jabbour, M. Konopleva, S. O'Brien, Z. Estrov, G. Borthakur, D. Thomas, S. Pierce, M. Brandt, K. Pratz, R. Luthra, M. Andreeff, H. Kantarjian

Research output: Contribution to journalLetter

49 Scopus citations
Original languageEnglish (US)
Pages (from-to)1543-1545
Number of pages3
JournalLeukemia
Volume28
Issue number7
DOIs
StatePublished - Jul 2014
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Ravandi, F., Arana Yi, C., Cortes, J. E., Levis, M., Faderl, S., Garcia-Manero, G., Jabbour, E., Konopleva, M., O'Brien, S., Estrov, Z., Borthakur, G., Thomas, D., Pierce, S., Brandt, M., Pratz, K., Luthra, R., Andreeff, M., & Kantarjian, H. (2014). Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia, 28(7), 1543-1545. https://doi.org/10.1038/leu.2014.54